Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 13, 2013 - Issue 11
Submit an article Journal homepage
135
Views
8
CrossRef citations to date
0
Altmetric
Theme: Bladder Cancer - Reviews

Lymph node-positive bladder cancer: surgical, pathologic, molecular and prognostic aspects

Jose A PedrosaDepartment of Urology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
,
Michael O KochDepartment of Urology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
&
Liang ChengDepartment of Urology, Indiana University School of Medicine, Indianapolis, IN 46202, USA;Departments of Pathology and Laboratory Medicine, Indiana University School of Medicine, 350 West 11th St, IUHPL 4044, Indianapolis, IN 46202, USACorrespondence[email protected]
Pages 1281-1295 | Published online: 10 Jan 2014

References

  • Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 63(1), 11–30 (2013).
  • Dangle PP, Gong MC, Bahnson RR, Pohar KS How do commonly performed lymphadenectomy templates influence bladder cancer nodal stage? J. Urol. 183(2), 499–503 (2010).
  • SteinJP, Cai J, Groshen S, Skinner DG Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density. J. Urol. 170(1), 35–41 (2003).
  • Lerner SP, Skinner DG, Lieskovsky G et al. The rationale for en bloc pelvic lymph node dissection for bladder cancer patients with nodal metastases: long-term results. J. Urol. 149(4), 758–764 (1993).
  • Skinner DG. Management of invasive bladder cancer: a meticulous pelvic node dissection can make a difference. J. Urol. 128(1), 34–36 (1982).
  • Abdollah F, Sun M, Schmitges J et al. Stage-specific impact of pelvic lymph node dissection on survival in patients with non-metastatic bladder cancer treated with radical cystectomy. BJU Int. 109(8), 1147–1154 (2012).
  • Herr HW, Bochner BH, Dalbagni G, Donat SM, Reuter VE, Bajorin DF. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J. Urol. 167(3), 1295–1298 (2002).
  • Park J, Park S, Song Cet al. Effectiveness of adjuvant chemotherapy in transitional cell carcinoma of the urinary bladder with lymph node involvement and/or lymphovascular invasion treated by radical cystectomy. Urology 70(2), 257–262 (2007).
  • Kassouf W, Agarwal PK, Grossman HB et al. Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. Urology 73(1), 147–152 (2009).
  • Bruins HM, Dorin RP. Rubino Bet al. Critical evaluation of the American Joint Committee on Cancer TNM nodal staging system in patients with lymph node-positive disease after radical cystectomy. Eur. Urol. 62(4), 671–676 (2012).
  • Herr HW. Superiority of ratio based lymph node staging for bladder cancer. J. Urol. 169(3), 943–945 (2003).
  • Fleischmann A, Thalmann GN, Markwalder R, Studer UE. Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor. J. Clin. Oncol. 23(10), 2358–2365 (2005).
  • Tarin TV, Power NE, Ehdaie B et al. Lymph node-positive bladder cancer treated with radical cystectomy and lymphadenectomy: effect of the level of node positivity. Eur. Urol. 61(5), 1025–1030 (2012).
  • Hurle R, Naspro R. Pelvic lymphadenectomy during radical cystectomy: a review of the literature. Surg. Oncol. 19(4), 208–220 (2010).
  • Knap MM, Lundbeck F, Overgaard J. The role of pelvic lymph node dissection as a predictive and prognostic factor in bladder cancer. Eur. J. Cancer 39(5), 604–613 (2003).
  • Jensen JB, Ulhoi BP, Jensen KM. Extended versus limited lymph node dissection in radical cystectomy: impact on recurrence pattern and survival. Int. J. Urol. 19(1), 39–47 (2012).
  • Herr HW, Faulkner JR, Grossman HB, Crawford ED. Pathologic evaluation of radical cystectomy specimens: a cooperative group report. Cancer 100(11), 2470–2475 (2004).
  • Hollenbeck BK, Ye Z, Wong SL, Montie JE, Birkmeyer JD. Hospital lymph node counts and survival after radical cystectomy. Cancer 112(4), 806–812 (2008).
  • Abdollah F, Sun M, Shariat SF et al. The importance of pelvic lymph node dissection in the elderly population: implications for interpreting the 2010 National Comprehensive Cancer Network practice guidelines for bladder cancer treatment. J. Urol. 185(6), 2078–2084 (2011).
  • Dhar NB, Campbell SC, Zippe CD et al. Outcomes in patients with urothelial carcinoma of the bladder with limited pelvic lymph node dissection. BJU Int. 98(6), 1172–1175 (2006).
  • Leissner J, Ghoneim MA, Abol-Enein H et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J. Urol. 171(1), 139–144 (2004).
  • Miocinovic R, Gong MC, Ghoneim IA, Fergany AF, Hansel DE, Stephenson AJ. Presacral and retroperitoneal lymph node involvement in urothelial bladder cancer: results of a prospective mapping study. J. Urol. 186(4), 1269–1273 (2011).
  • Abol-Enein H, El-Baz M, Abd El-Hameed MA, Abdel-Latif M, Ghoneim MA. Lymph node involvement in patients with bladder cancer treated with radical cystectomy: a patho-anatomical study--a single center experience. J. Urol. 172(5 Pt 1), 1818–1821 (2004).
  • Vazina A, Dugi D, Shariat SF, Evans J, Link R, Lerner SP. Stage specific lymph node metastasis mapping in radical cystectomy specimens. J. Urol. 171(5), 1830–1834 (2004).
  • Steven K, Poulsen AL. Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only. J. Urol. 178(4 Pt 1), 1218–1223 (2007).
  • Zehnder P, Studer UE. Skinner EC et al. Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. J. Urol. 186(4), 1261–1268 (2011).
  • Bochner BH, Cho D, Herr HW, Donat M, Kattan MW, Dalbagni G. Prospectively packaged lymph node dissections with radical cystectomy: evaluation of node count variability and node mapping. J. Urol. 172(4 Pt 1), 1286–1290 (2004).
  • Dhar NB, Klein EA, Reuther AM, Thalmann GN, Madersbacher S, Studer UE. Outcome after radical cystectomy with limited or extended pelvic lymph node dissection. J. Urol. 179(3), 873–878 (2008).
  • Simone G, Papalia R, Ferriero M et al. Stage-specific impact of extended versus standard pelvic lymph node dissection in radical cystectomy. Int. J. Urol. 20(4), 390–397 (2013).
  • Poulsen AL, Horn T, Steven K. Radical cystectomy: extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall. J. Urol. 160(6 Pt 1), 2015–2019 (1998).
  • Abol-Enein H, Tilki D, Mosbah A et al. Does the extent of lymphadenectomy in radical cystectomy for bladder cancer influence disease-free survival? A prospective single-center study. Eur. Urol. 60(3), 572–577 (2011).
  • Leissner J, Hohenfellner R, Thuroff JW, Wolf HK. Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis. BJU Int. 85(7), 817–823 (2000).
  • Brossner C, Pycha A, Toth A, Mian C, Kuber W. Does extended lymphadenectomy increase the morbidity of radical cystectomy? BJU Int. 93(1), 64–66 (2004).
  • Bochner BH, Herr HW, Reuter VE Impact of separate versus en bloc pelvic lymph node dissection on the number of lymph nodes retrieved in cystectomy specimens. J. Urol. 166(6), 2295–2296 (2001).
  • Stein JP, Penson DF, Cai J et al. Radical cystectomy with extended lymphadenectomy: evaluating separate package versus en bloc submission for node positive bladder cancer. J. Urol. 177(3), 876–881 (2007).
  • Ather MH, Alam Z, Jamshaid A, Siddiqui KM, Sulaiman MN Separate submission of standard lymphadenectomy in 6 packets versus en bloc lymphadenectomy in bladder cancer. Urol. J. 5(2), 94–98 (2008).
  • Algaba F, Arce Y, Lopez-Beltran A, Montironi R, Mikuz G, Bono AV. Intraoperative frozen section diagnosis in urological oncology. Eur. Urol. 47(2), 129–136 (2005).
  • Sherif A, De La Torre M, Malmstrom PU, Thorn M. Lymphatic mapping and detection of sentinel nodes in patients with bladder cancer. J. Urol. 166(3), 812–815 (2001).
  • Roth B, Wissmeyer MP, Zehnder P et al. A new multimodality technique accurately maps the primary lymphatic landing sites of the bladder. Eur. Urol. 57(2), 205–211 (2010).
  • Roth B, Zehnder P, Birkhauser FD, Burkhard FC, Thalmann GN, Studer UE Is bilateral extended pelvic lymphadenectomy necessary for strictly unilateral invasive bladder cancer? J. Urol. 187(5), 1577–1582 (2012).
  • Ugurlu O, Adsan O, Tul M, Kosan M, Inal G, Cetinkaya M. Value of frozen sections of lymph nodes in pelvic lymphadenectomy in patients with invasive bladder tumor. Int. J. Urol. 13(6), 699–702 (2006).
  • Liedberg F, Chebil G, Davidsson T, Gudjonsson S, Mansson W. Intraoperative sentinel node detection improves nodal staging in invasive bladder cancer. J. Urol. 175(1), 84–88 (2006).
  • Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349(9), 859–866 (2003).
  • von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J. Clin. Oncol. 18(17), 3068–3077 (2000).
  • Loehrer PJ, Sr., Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol. 10(7), 1066–1073 (1992).
  • Advanced Bladder Cancer Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur. Urol. 48(2), 189–199 (2005).
  • Frank I, Cheville JC, Blute ML et al. Transitional cell carcinoma of the urinary bladder with regional lymph node involvement treated by cystectomy: clinicopathologic features associated with outcome. Cancer 97(10), 2425–2431 (2003).
  • Jeong IG, Ro JY, Kim SC et al. Extranodal extension in node-positive bladder cancer: the continuing controversy. BJU Int. 108(1), 38–43 (2011).
  • Gofrit ON, Stadler WM, Zorn KC et al. Adjuvant chemotherapy in lymph node positive bladder cancer. Urol. Oncol. 27(2), 160–164 (2009).
  • Svatek RS, Shariat SF, Lasky RE et al. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin. Cancer Res. 16(17), 4461–4467 (2010).
  • Meijer RP, Nunnink CJ, Wassenaar AE et al. Standard lymph node dissection for bladder cancer: significant variability in the number of reported lymph nodes. J. Urol. 187(2), 446–450 (2012).
  • Fang AC, Ahmad AE, Whitson JM, Ferrell LD, Carroll PR, Konety BR. Effect of a minimum lymph node policy in radical cystectomy and pelvic lymphadenectomy on lymph node yields, lymph node positivity rates, lymph node density, and survivorship in patients with bladder cancer. Cancer 116(8), 1901–1908 (2010).
  • Reese JA, Hall C, Bowles K, Moesinger RC. Colorectal surgical specimen lymph node harvest: improvement of lymph node yield with a pathology assistant. J. Gastrointest. Surg. 13(8), 1459–1463 (2009).
  • Koren R, Paz A, Lask D et al. Lymph-node revealing solution: a new method for detecting minute lymph nodes in cystectomy specimens. Br. J. Urol. 80(1), 40–43 (1997).
  • Gordetsky J, Scosyrev E, Rashid H et al. Identifying additional lymph nodes in radical cystectomy lymphadenectomy specimens. Mod. Pathol. 25(1), 140–144 (2012).
  • Parkash V, Bifulco C, Feinn R, Concato J, Jain D. To count and how to count, that is the question: interobserver and intraobserver variability among pathologists in lymph node counting. Am. J. Clin. Pathol. 134(1), 42–49 (2010).
  • Koppie TM, Vickers AJ, Vora K, Dalbagni G, Bochner BH Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed? Cancer 107(10), 2368–2374 (2006).
  • Wright JL, Lin DW, Porter MP. The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy. Cancer 112(11), 2401–2408 (2008).
  • Morgan TM, Barocas DA, Penson DF et al. Lymph node yield at radical cystectomy predicts mortality in node-negative and not node-positive patients. Urology 80(3), 632–640 (2012).
  • Gofrit ON, Zorn KC, Steinberg GD, Zagaja GP, Shalhav AL. The Will Rogers phenomenon in urological oncology. J. Urol. 179(1), 28–33 (2008).
  • Herr HW, Smith JA, Montie JE. Standardization of radical cystectomy: time to count and be counted. BJU Int. 94(4), 481–482 (2004).
  • Capitanio U, Suardi N, Shariat SF et al. Assessing the minimum number of lymph nodes needed at radical cystectomy in patients with bladder cancer. BJU Int. 103(10), 1359–1362 (2009).
  • Shariat SF, Ehdaie B, Rink M et al. Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment. Eur. Urol. 61(2), 237–242 (2012).
  • Weingartner K, Ramaswamy A, Bittinger A, Gerharz EW, Voge D, Riedmiller H. Anatomical basis for pelvic lymphadenectomy in prostate cancer: results of an autopsy study and implications for the clinic. J. Urol. 156(6), 1969–1971 (1996).
  • Jensen JB, Ulhoi BP, Jensen KM. Size and volume of metastatic and non-metastatic lymph nodes in pelvis and lower abdomen in patients with carcinoma of the bladder undergoing radical cystectomy. Scand. J. Urol. Nephrol. 44(5), 291–297 (2010).
  • Thompson RH, Carver BS, Bosl GJ et al. Body mass index is associated with higher lymph node counts during retroperitoneal lymph node dissection. Urology 79(2), 361–364 (2012).
  • Dorin RP, Daneshmand S, Eisenberg MS et al. Lymph node dissection technique is more important than lymph node count in identifying nodal metastases in radical cystectomy patients: a comparative mapping study. Eur. Urol. 60(5), 946–952 (2011).
  • Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 19(3), 666–675 (2001).
  • Honma I, Masumori N, Sato E et al. Removal of more lymph nodes may provide better outcome, as well as more accurate pathologic findings, in patients with bladder cancer--analysis of role of pelvic lymph node dissection. Urology 68(3), 543–548 (2006).
  • Bruins HM, Huang GJ, Cai J, Skinner DG, Stein JP, Penson DF. Clinical outcomes and recurrence predictors of lymph node positive urothelial cancer after cystectomy. J. Urol. 182(5), 2182–2187 (2009).
  • Jeong IG, You D, Kim JW et al. Outcomes of single lymph node positive urothelial carcinoma after radical cystectomy. J. Urol. 185(6), 2085–2090 (2011).
  • Jensen JB, Ulhoi BP, Jensen KM. Evaluation of different lymph node (LN) variables as prognostic markers in patients undergoing radical cystectomy and extended LN dissection to the level of the inferior mesenteric artery. BJU Int. 109(3), 388–393 (2012).
  • Kassouf W, Agarwal PK, Herr HW et al. Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. J. Clin. Oncol. 26(1), 121–126 (2008).
  • Kassouf W, Leibovici D, Munsell MF, Dinney CP, Grossman HB, Kamat AM. Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy. J. Urol. 176(1), 53–57 (2006).
  • Lee EK, Herr HW, Dickstein RJ et al. Lymph node density for patient counselling about prognosis and for designing clinical trials of adjuvant therapies after radical cystectomy. BJU Int 110(11 Pt B), E590–E595 (2012).
  • Osawa T, Abe T, Shinohara N et al. Role of lymph node density in predicting survival of patients with lymph node metastases after radical cystectomy: a multi-institutional study. Int. J. Urol. 16(3), 274–278 (2009).
  • Simone G, Papalia R, Ferriero M et al. Development and external validation of lymph node density cut-off points in prospective series of radical cystectomy and pelvic lymph node dissection. Int. J. Urol. 19(12), 1068–1074 (2012).
  • Wiesner C, Salzer A, Thomas C et al. Cancer-specific survival after radical cystectomy and standardized extended lymphadenectomy for node-positive bladder cancer: prediction by lymph node positivity and density. BJU Int. 104(3), 331–335 (2009).
  • Cheng CW, Ng CF, Chan CK, Wong WS, Hui PE, Wong YF. A fourteen-year review of radical cystectomy for transitional cell carcinoma demonstrating the usefulness of the concept of lymph node density. Int. Braz. J. Urol. 32(5), 536–549 (2006).
  • Kassouf W, Svatek RS, Shariat SF et al. Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. Urol. Oncol. 31(4), 480–486 (2013).
  • May M, Herrmann E, Bolenz C et al. Lymph node density affects cancer-specific survival in patients with lymph node-positive urothelial bladder cancer following radical cystectomy. Eur. Urol. 59(5), 712–718 (2011).
  • Stephenson AJ, Gong MC, Campbell SC, Fergany AF, Hansel DE. Aggregate lymph node metastasis diameter and survival after radical cystectomy for invasive bladder cancer. Urology 75(2), 382–386 (2010).
  • Mills RD, Turner WH, Fleischmann A, Markwalder R, Thalmann GN, Studer UE. Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy. J. Urol. 166(1), 19–23 (2001).
  • Seiler R, von Gunten M, Thalmann GN, Fleischmann A. Extracapsular extension but not the tumour burden of lymph node metastases is an independent adverse risk factor in lymph node-positive bladder cancer. Histopathology 58(4), 571–578 (2011).
  • Seiler R, von Gunten M, Thalmann GN, Fleischmann A. Pelvic lymph nodes: distribution and nodal tumour burden of urothelial bladder cancer. J. Clin. Pathol. 63(6), 504–507 (2010).
  • Fleischmann A, Thalmann GN, Markwalder R, Studer UE. Prognostic implications of extracapsular extension of pelvic lymph node metastases in urothelial carcinoma of the bladder. Am. J. Surg. Pathol. 29(1), 89–95 (2005).
  • Masson-Lecomte A, Vordos D, Hoznek A et al. External validation of extranodal extension and lymph node density as predictors of survival in node-positive bladder cancer after radical cystectomy. Ann. Surg. Oncol. 20(4), 1389–1394 (2013).
  • Fajkovic H, Cha EK, Jeldres C et al. Extranodal extension is a powerful prognostic factor in bladder cancer patients with lymph node metastasis. Eur. Urol. doi: 0.1016/j.eururo.2012.07.026 (2012) (Epub ahead of print).
  • Gibson UE, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res 6(10), 995–1001 (1996).
  • Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res. 6(10), 986–994 (1996).
  • Keene SA, Demeure MJ. The clinical significance of micrometastases and molecular metastases. Surgery 129(1), 1–5 (2001).
  • Malmstrom PU, Ren ZP, Sherif A, de la Torre M, Wester K, Thorn M. Early metastatic progression of bladder carcinoma: molecular profile of primary tumor and sentinel lymph node. J. Urol. 168(5), 2240–2244 (2002).
  • Singletary SE, Allred C, Ashley P et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J. Clin. Oncol. 20(17), 3628–3636 (2002).
  • Prognostic importance of occult axillary lymph node micrometastases from breast cancers. International (Ludwig) Breast Cancer Study Group. Lancet 335(8705), 1565–1568 (1990).
  • Watts KL, Ristau BT, Yamase HT, Taylor JA 3rd. Prognostic implications of lymph node involvement in bladder cancer: are we understaging using current methods? BJU Int. 108(4), 484–492 (2011).
  • Retz M, Lehmann J, Szysnik C et al. Detection of occult tumor cells in lymph nodes from bladder cancer patients by MUC7 nested RT-PCR. Eur. Urol. 45(3), 314–319 (2004).
  • Seraj MJ, Thomas AR, Chin JL, Theodorescu D. Molecular determination of perivesical and lymph node metastasis after radical cystectomy for urothelial carcinoma of the bladder. Clin. Cancer Res. 7(6), 1516–1522 (2001).
  • Wu X, Kakehi Y, Zeng Y, Taoka R, Tsunemori H, Inui M. Uroplakin II as a promising marker for molecular diagnosis of nodal metastases from bladder cancer: comparison with cytokeratin 20. J. Urol. 174(6), 2138–2142 (2005).
  • Jiang J, Ulbright TM, Younger C et al. Cytokeratin 7 and cytokeratin 20 in primary urinary bladder carcinoma and matched lymph node metastasis. Arch. Pathol. Lab Med. 125(7), 921–923 (2001).
  • Frank I, Cheville JC, Blute ML et al. Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement. Cancer 101(8), 1803–1808 (2004).
  • Kurahashi T, Hara I, Oka N, Kamidono S, Eto H, Miyake H. Detection of micrometastases in pelvic lymph nodes in patients undergoing radical cystectomy for locally invasive bladder cancer by real-time reverse transcriptase-PCR for cytokeratin 19 and uroplakin II Clin. Cancer Res. 11(10), 3773–3777 (2005).
  • Copp HL, Chin JL, Conaway M, Theodorescu D. Prospective evaluation of the prognostic relevance of molecular staging for urothelial carcinoma. Cancer 107(1), 60–66 (2006).
  • Marin-Aguilera M, Mengual L, Burset M et al. Molecular lymph node staging in bladder urothelial carcinoma: impact on survival. Eur. Urol. 54(6), 1363–1372 (2008).
  • Mitra AP, Almal AA, George B et al. The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer. BMC Cancer 6, 159 (2006).
  • Hegele A, Mecklenburg V, Varga Z, Olbert P, Hofmann R, Barth P. CA19.9 and CEA in transitional cell carcinoma of the bladder: serological and immunohistochemical findings. Anticancer Res. 30(12), 5195–5200 (2010).
  • Cook AM, Huddart RA, Jay G, Norman A, Dearnaley DP, Horwich A. The utility of tumour markers in assessing the response to chemotherapy in advanced bladder cancer. Br J Cancer 82(12), 1952–1957 (2000).
  • Kamat AM, Hegarty PK, Gee JR et al. ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers. Eur. Urol. 63(1), 4–15 (2013).
  • Szarvas T, Becker M, vom Dorp F et al. Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer. Cancer Sci. 101(5), 1300–1308 (2010).
  • Svatek RS, Shah JB, Xing J et al. A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with bladder cancer. Cancer 116(19), 4513–4519 (2010).
  • Naoe M, Ogawa Y, Morita J et al. Detection of circulating urothelial cancer cells in the blood using the CellSearch System. Cancer 109(7), 1439–1445 (2007).
  • Gallagher DJ, Milowsky MI, Ishill N et al. Detection of circulating tumor cells in patients with urothelial cancer. Ann. Oncol. 20(2), 305–308 (2009).
  • Flaig TW, Wilson S, van Bokhoven A et al. Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma. Urology 78(4), 863–867 (2011).
  • Nezos A, Pissimisis N, Lembessis P et al. Detection of circulating tumor cells in bladder cancer patients. Cancer Treat. Rev. 35(3), 272–279 (2009).
  • Msaouel P, Koutsilieris M. Diagnostic value of circulating tumor cell detection in bladder and urothelial cancer: systematic review and meta-analysis. BMC Cancer 11, 336 (2011).
  • Richter S, Sridhar SS. New directions for biologic targets in urothelial carcinoma. Mol. Cancer Ther. 11(6), 1226–1235 (2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.